Idun Pharmaceuticals Inc is categorized under Medical Research in San Diego, CA and active since 2010.
Idun Pharmaceuticals Inc was established in 2010, and today employs 1 to 4, earning $2.500.000 to $4.999.999 per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Martin Mackay at the company’s single location by writing to 9380 Judicial Drive, San Diego, California CA 92121 or by phoning (858) 622-3000. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Idun Pharmaceuticals Inc |
| Contact Person: | Martin Mackay |
| Address: | 9380 Judicial Drive, San Diego, California 92121 |
| Phone Number: | (858) 622-3000 |
| Website Address: | conatuspharma.com |
| Annual Revenue (USD): | $2.500.000 to $4.999.999 |
| Founded: | 2010 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Medical Research |
| SIC Code: | 8733 |
| NAICS Code: | 541720 |
| Share This Business: |
Idun Pharmaceuticals Inc was started in 2010 to provide professional Medical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $2.500.000 to $4.999.999 per annum.
Feel free to contact Martin Mackay for inquiries that concern Idun Pharmaceuticals Inc by calling the company number (858) 622-3000, as your correspondence is most welcome. Additionally, the physical location of the single location of Idun Pharmaceuticals Inc can be found at the coordinates 32.879185,-117.205702 as well as the street address 9380 Judicial Drive in San Diego, California 92121.
For its online presence, you may visit Idun Pharmaceuticals Inc’s website at conatuspharma.com and engage with its social media outlets through on Twitter and on Facebook.